8-K: Corvus Soquelitinib Shines in Atopic Dermatitis Phase 1

Corvus Pharmaceuticals announced positive Phase 1 clinical trial results for soquelitinib in moderate to severe atopic dermatitis, showing favorable safety and efficacy and plans for a Phase 2 trial.

Summary

• Positive results were reported from cohort 4 of the randomized, blinded, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis.
• Cohort 4 data demonstrated favorable safety and efficacy results consistent with results from cohorts 1-3, including a deepening of responses over an 8-week treatment period compared to the 4-week period used in earlier cohorts.
• Clinical activity was observed in patients who had received prior systemic therapies, including those resistant to therapies like dupilumab and JAK inhibitors.
• At day 56, the mean percent reduction in EASI (Eczema Area and Severity Index) for patients receiving soquelitinib in cohort 4 (n=12) was 70% (72% in the press release), compared to 40% for patients receiving placebo (n=10).
• EASI 75, EASI 90, and IGA (Investigator Global Assessment) 0/1 for soquelitinib patients in cohort 4 were achieved in 75%, 25%, and 33% of patients, respectively, compared to 20%, 0%, and 0% for the placebo group.
• The difference in the EASI reduction curves at day 56 was statistically significant (p=0.035).
• No new safety signals were observed; reported adverse events occurred in 41.7% of soquelitinib patients and 50% of placebo patients, all were Grade 1-2 and did not result in dose modifications or interruptions.
• Biomarker data supported the novel proposed mechanism of action with ITK inhibition, showing reductions in serum IL-4, IL-5, IL-17, TARC, and circulating Th2 cells, alongside an increase in circulating Treg cells, suggesting immune system rebalancing.
• Based on these positive results, the company plans to initiate a Phase 2 trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis who have failed at least one prior topical or systemic therapy in the first quarter of 2026.

Sentiment

Score: 8

Explanation: The filing reports strong positive Phase 1 clinical trial results for soquelitinib in atopic dermatitis, demonstrating significant efficacy and a favorable safety profile, even in treatment-resistant patients. The planned progression to Phase 2 and supportive biomarker data are highly encouraging for the drug's potential.

Positives

• Soquelitinib demonstrated favorable safety and efficacy results in patients with moderate to severe atopic dermatitis.
• Longer 8-week treatment in cohort 4 led to a deepening of clinical responses, with continuous improvement from day 28 to day 56.
• The drug showed clinical activity in patients who had received prior systemic therapies, including those resistant to dupilumab and JAK inhibitors.
• A statistically significant difference in EASI reduction was observed compared to placebo at day 56 (p=0.035).
• No new safety signals were observed, with all reported adverse events being mild (Grade 1-2) and no severe or serious adverse events.
• Biomarker data supports the novel ITK inhibition mechanism, indicating an immune system rebalancing involving Th1, Th2, Th17, and Treg cells.
• The company is on track to initiate a Phase 2 clinical trial for soquelitinib in Q1 2026, indicating rapid progression based on positive data.

Negatives

• Two out of twelve enrolled placebo patients in cohort 4 were non-compliant and missed the day 56 visit, affecting the evaluable patient count for the placebo group.
• Two placebo patients experienced disease flares requiring therapy during the 56-day treatment period, compared to none in the soquelitinib group.
• Not all patients had completed the 30-day post-treatment follow-up at the time of the report.

Risks

• The company's ability to demonstrate sufficient evidence of efficacy and safety in its clinical trials of product candidates.
• The accuracy of the company's estimates relating to its ability to initiate and/or complete preclinical studies and clinical trials and release data from such studies and clinical trials.
• The results of preclinical studies and interim data from clinical trials not being predictive of future results.
• The company's ability to enroll sufficient numbers of patients in its clinical trials.
• The unpredictability of the regulatory process.
• Regulatory developments in the United States and foreign countries.
• The costs of clinical trials may exceed expectations.
• The company's ability to accurately estimate the cash on hand providing funding into the fourth quarter of 2026.
• The company's ability to raise additional capital.

Future Outlook

The company plans to initiate a Phase 2 clinical trial for soquelitinib in patients with moderate to severe atopic dermatitis who have failed at least one prior topical or systemic therapy in the first quarter of 2026. This trial is anticipated to enroll approximately 200 patients across four cohorts with different dosing regimens (200 mg once daily, 200 mg twice daily, 400 mg once daily, and a placebo group) over a 12-week treatment period with a 30-day follow-up.

Management Comments

• "The results from cohort 4 increase our confidence that soquelitinib could become a leading oral therapy for the treatment of atopic dermatitis." Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus.
• "The results also support our hypothesis from cohort 3 that the longer treatment could achieve deepening of clinical responses." Richard A. Miller, M.D.
• "Bottom line, we believe this is a successful Phase 1 program and the results have become stronger the longer we treat, without compromising safety." Richard A. Miller, M.D.
• "We believe this bodes well for advancing soquelitinib to the next phase where we will further test soquelitinib in a larger patient population." Richard A. Miller, M.D.
• "Taken altogether, we believe the data indicate that soquelitinib has the potential to be an important new medicine for first line or later line therapy of patients with atopic dermatitis that could be among the most active approved or investigational drugs for this indication." Richard A. Miller, M.D.
• "The data to-date also supports the novel proposed mechanism of action with ITK inhibition, which is designed to act upstream and regulate multiple T cell functional pathways. The immune rebalancing indicated thus far by soquelitinib shows its potential in a wide range of inflammatory and immune diseases." Richard A. Miller, M.D.

Industry Context

Atopic dermatitis is a chronic inflammatory skin disease affecting a significant portion of the population, with existing treatments including topical, oral, and systemic biologic therapies. Soquelitinib's novel ITK inhibition mechanism, which targets T cell functional pathways and promotes immune rebalancing, positions it as a potential new oral therapeutic option. Its demonstrated efficacy in patients resistant to current systemic therapies like dupilumab and JAK inhibitors suggests it could address a critical unmet need in the atopic dermatitis market.

Comparison to Industry Standards

• Soquelitinib demonstrated clinical activity in patients who had received prior systemic therapies, including those resistant to therapies like dupilumab and JAK inhibitors, suggesting a potential advantage over existing treatments for this patient population.
• Management believes soquelitinib has the potential to be an important new medicine for first line or later line therapy of patients with atopic dermatitis that could be among the most active approved or investigational drugs for this indication.

Stakeholder Impact

• Shareholders: Positive clinical trial results and the planned progression to Phase 2 could increase investor confidence and potentially enhance the company's valuation.
• Patients (Atopic Dermatitis): Soquelitinib offers a promising new oral treatment option, particularly for those who have failed existing systemic therapies, addressing an unmet medical need.
• Employees: Positive clinical progress can boost morale and potentially contribute to job security and growth opportunities.
• Competitors: The successful development of soquelitinib could introduce a new competitive oral therapy into the atopic dermatitis market, potentially impacting existing drug sales and development pipelines.

Next Steps

• Initiate a Phase 2 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis that have failed at least one prior topical or systemic therapy in the first quarter of 2026.
• Enroll approximately 200 patients in the Phase 2 trial across four cohorts (200 mg once per day; 200 mg twice per day; 400 mg once per day; and a placebo group).
• Conduct a 12-week treatment period with a 30-day follow-up period with no treatment in the Phase 2 trial.
• Continue follow-up for patients in cohort 4 beyond the 56-day treatment period.

Key Dates

Recommendation

The positive Phase 1 results for soquelitinib in atopic dermatitis are highly compelling, demonstrating strong efficacy (70-72% EASI reduction vs 40% for placebo, 75% EASI 75 vs 20% for placebo) and an excellent safety profile (no severe adverse events, fewer AEs than placebo). Crucially, the drug showed activity in patients resistant to current systemic therapies like dupilumab and JAK inhibitors, addressing a significant unmet medical need. The clear path to a Phase 2 trial in Q1 2026, coupled with supportive biomarker data and management's confident outlook, suggests a high probability of continued clinical success and significant market potential for this novel oral therapy. This represents a strong de-risking event for the asset and the company.

Keywords

Corvus Pharmaceuticals, CRVS, soquelitinib, atopic dermatitis, eczema, Phase 1 clinical trial, ITK inhibition, immunology, biopharmaceutical, clinical-stage, dermatology, dupilumab, JAK inhibitors, EASI, IGA, immune rebalancing